Cargando…

Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis

Prostate cancer is the product of dysregulated homeostasis within the aging prostate. Supplementation with selenium in the form of selenized yeast (Se-yeast) significantly reduced prostate cancer incidence in the Nutritional Prevention of Cancer Trial. Conversely, the Selenium and Vitamin E Cancer P...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, David J., Shen, Shuren, Kengeri, Seema S., Chiang, Emily C., Combs, Gerald F., Morris, J. Steven, Bostwick, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509511/
https://www.ncbi.nlm.nih.gov/pubmed/23201838
http://dx.doi.org/10.3390/nu4111650
_version_ 1782251344328916992
author Waters, David J.
Shen, Shuren
Kengeri, Seema S.
Chiang, Emily C.
Combs, Gerald F.
Morris, J. Steven
Bostwick, David G.
author_facet Waters, David J.
Shen, Shuren
Kengeri, Seema S.
Chiang, Emily C.
Combs, Gerald F.
Morris, J. Steven
Bostwick, David G.
author_sort Waters, David J.
collection PubMed
description Prostate cancer is the product of dysregulated homeostasis within the aging prostate. Supplementation with selenium in the form of selenized yeast (Se-yeast) significantly reduced prostate cancer incidence in the Nutritional Prevention of Cancer Trial. Conversely, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no such cancer-protective advantage using selenomethionine (SeMet). The possibility that SeMet and Se-yeast are not equipotent in promoting homeostasis and cancer risk reduction in the aging prostate has not been adequately investigated; no direct comparison has ever been reported in man or animals. Here, we analyzed data on prostatic responses to SeMet or Se-yeast from a controlled feeding trial of 49 elderly beagle dogs—the only non-human species to frequently develop prostate cancer during aging—randomized to one of five groups: control; low-dose SeMet, low-dose Se-yeast (3 μg/kg); high-dose SeMet, high-dose Se-yeast (6 μg/kg). After seven months of supplementation, we found no significant selenium form-dependent differences in toenail or intraprostatic selenium concentration. Next, we determined whether SeMet or Se-yeast acts with different potency on six markers of prostatic homeostasis that likely contribute to prostate cancer risk reduction—intraprostatic dihydrotestosterone (DHT), testosterone (T), DHT:T, and epithelial cell DNA damage, proliferation, and apoptosis. By analyzing dogs supplemented with SeMet or Se-yeast that achieved equivalent intraprostatic selenium concentration after supplementation, we showed no significant differences in potency of either selenium form on any of the six parameters over three different ranges of target tissue selenium concentration. Our findings, which represent the first direct comparison of SeMet and Se-yeast on a suite of readouts in the aging prostate that reflect flux through multiple gene networks, do not further support the notion that the null results of SELECT are attributable to differences in prostatic consequences achievable through daily supplementation with SeMet, rather than Se-yeast.
format Online
Article
Text
id pubmed-3509511
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-35095112012-12-18 Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis Waters, David J. Shen, Shuren Kengeri, Seema S. Chiang, Emily C. Combs, Gerald F. Morris, J. Steven Bostwick, David G. Nutrients Article Prostate cancer is the product of dysregulated homeostasis within the aging prostate. Supplementation with selenium in the form of selenized yeast (Se-yeast) significantly reduced prostate cancer incidence in the Nutritional Prevention of Cancer Trial. Conversely, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no such cancer-protective advantage using selenomethionine (SeMet). The possibility that SeMet and Se-yeast are not equipotent in promoting homeostasis and cancer risk reduction in the aging prostate has not been adequately investigated; no direct comparison has ever been reported in man or animals. Here, we analyzed data on prostatic responses to SeMet or Se-yeast from a controlled feeding trial of 49 elderly beagle dogs—the only non-human species to frequently develop prostate cancer during aging—randomized to one of five groups: control; low-dose SeMet, low-dose Se-yeast (3 μg/kg); high-dose SeMet, high-dose Se-yeast (6 μg/kg). After seven months of supplementation, we found no significant selenium form-dependent differences in toenail or intraprostatic selenium concentration. Next, we determined whether SeMet or Se-yeast acts with different potency on six markers of prostatic homeostasis that likely contribute to prostate cancer risk reduction—intraprostatic dihydrotestosterone (DHT), testosterone (T), DHT:T, and epithelial cell DNA damage, proliferation, and apoptosis. By analyzing dogs supplemented with SeMet or Se-yeast that achieved equivalent intraprostatic selenium concentration after supplementation, we showed no significant differences in potency of either selenium form on any of the six parameters over three different ranges of target tissue selenium concentration. Our findings, which represent the first direct comparison of SeMet and Se-yeast on a suite of readouts in the aging prostate that reflect flux through multiple gene networks, do not further support the notion that the null results of SELECT are attributable to differences in prostatic consequences achievable through daily supplementation with SeMet, rather than Se-yeast. MDPI 2012-11-06 /pmc/articles/PMC3509511/ /pubmed/23201838 http://dx.doi.org/10.3390/nu4111650 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Waters, David J.
Shen, Shuren
Kengeri, Seema S.
Chiang, Emily C.
Combs, Gerald F.
Morris, J. Steven
Bostwick, David G.
Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title_full Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title_fullStr Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title_full_unstemmed Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title_short Prostatic Response to Supranutritional Selenium Supplementation: Comparison of the Target Tissue Potency of Selenomethionine vs. Selenium-Yeast on Markers of Prostatic Homeostasis
title_sort prostatic response to supranutritional selenium supplementation: comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509511/
https://www.ncbi.nlm.nih.gov/pubmed/23201838
http://dx.doi.org/10.3390/nu4111650
work_keys_str_mv AT watersdavidj prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT shenshuren prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT kengeriseemas prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT chiangemilyc prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT combsgeraldf prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT morrisjsteven prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis
AT bostwickdavidg prostaticresponsetosupranutritionalseleniumsupplementationcomparisonofthetargettissuepotencyofselenomethioninevsseleniumyeastonmarkersofprostatichomeostasis